Announced
Synopsis
Biotage, a life science company, agreed to acquire Astrea Bioseparations, a biotechnology research company, from KKR-backed Gamma Biosciences, a biotechnology company, for $235m. "This move brings together two highly regarded and complementary businesses creating a differentiated player in the field of chromatography. Astrea is quickly becoming one of the leaders in its field with an incredible pipeline of innovation targeting advanced therapeutics. We are excited to join forces with the team at Biotage and leverage the strong foundation that they've established to rapidly grow these businesses together," Matt Gunnison, Gamma Biosciences CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.